Tegsedi 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued 2 / 
affected 3  
amended 
on 
IB/0040 
B.II.b.3.z - Change in the manufacturing process of 
13/12/2023 
n/a 
the finished or intermediate product - Other variation 
II/0038 
Update of sections 4.4 and 4.8 of the SmPC in order 
30/11/2023 
SmPC, Annex 
Please refer to Scientific Discussion ‘Tegsedi-H-C-004782-
to modify the warning on liver monitoring and drug-
induced liver injury and to add ‘drug-induced liver 
II and PL 
II-Var.38’. 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
injury’ to the list of adverse drug reactions (ADRs) 
with frequency not known, following the request in 
the Assessment Report for PAM procedure 
EMEA/H/C/004782/LEG/008. The Annex II and 
Package Leaflet are updated accordingly. The RMP 
version 4.2 has also been submitted. In addition, the 
MAH took the opportunity to introduce minor updates 
to the PI. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
Amendments to the SmPC to modify the warning on liver 
monitoring and drug-induced liver injury and to add ‘drug-
induced liver injury’ to the list of adverse drug reactions. 
Update of the risk management plan to include 
Hepatotoxicity as a new important identified risk. Additional 
Risk Minimization Measures (patient alert cards) are also 
updated accordingly. The Annex II and Package Leaflet are 
also updated and in addition, the MAH took the opportunity 
to introduce minor updates to the PI. 
For more information, please refer to the Summary of 
Product Characteristics. 
IAIN/0037 
B.II.b.1.a - Replacement or addition of a 
10/07/2023 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
PSUSA/10697
Periodic Safety Update EU Single assessment - 
23/02/2023 
19/04/2023 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/202207 
inotersen 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10697/202207. 
R/0035 
Renewal of the marketing authorisation. 
26/01/2023 
24/03/2023 
SmPC and PL 
Based on the review of data on quality, safety and efficacy, 
the CHMP considered that the benefit-risk balance of 
Tegsedi in the approved indication remains favourable and 
therefore recommended the renewal of the marketing 
authorisation with unlimited validity. 
II/0034 
Submission of the final report from study ISIS 
09/03/2023 
n/a 
Submission of the final report from Open-Label Extension 
420915-CS3, listed as a category 3 in the RMP. This 
is an Open-Label Extension Study to Assess the 
Long-Term Safety and Efficacy of ISIS 420915 in 
Patients with Familial Amyloid Polyneuropathy (FAP). 
Study to Assess the Long-Term Safety and Efficacy in 
Patients with Familial Amyloid Polyneuropathy (FAP). 
Page 2/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
IAIN/0036 
A.1 - Administrative change - Change in the name 
07/11/2022 
24/03/2023 
SmPC, 
and/or address of the MAH 
Labelling and 
PL 
IB/0031 
C.I.z - Changes (Safety/Efficacy) of Human and 
15/10/2022 
24/03/2023 
Annex II 
Veterinary Medicinal Products - Other variation 
IA/0033/G 
This was an application for a group of variations. 
19/09/2022 
n/a 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
IA/0030 
B.II.b.5.a - Change to in-process tests or limits 
22/08/2022 
n/a 
applied during the manufacture of the finished 
Page 3/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
product - Tightening of in-process limits 
IA/0029/G 
This was an application for a group of variations. 
08/08/2022 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
IB/0028 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
28/07/2022 
21/09/2022 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
IB/0027 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
27/07/2022 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
II/0026 
Updated RMP version 3.1 removes carcinogenicity in 
10/03/2022 
n/a 
rats as missing information, adds a targeted 
questionnaire as routine pharmacovigilance measure 
Page 4/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
and a patient alert card as additional risk 
minimisation for liver transplant rejection. Adds 
'injection site reactions' and 'immunogenicity' as 
risks not considered important for inclusion in the 
summary of safety concerns (SVII.1.) and updates 
the patient alert card with additional warnings on 
hepatic monitoring and ocular toxicity. Further 
sections of the RMP are updated. 
C.I.11.b - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
change(s) which require to be further substantiated 
by new additional data to be submitted by the MAH 
where significant assessment is required 
PSUSA/10697
Periodic Safety Update EU Single assessment - 
10/02/2022 
n/a 
PRAC Recommendation - maintenance 
/202107 
inotersen 
PSUSA/10697
Periodic Safety Update EU Single assessment - 
16/09/2021 
09/11/2021 
SmPC 
Refer to Scientific conclusions and grounds recommending 
/202101 
inotersen 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10697/202101. 
IB/0024 
C.I.z - Changes (Safety/Efficacy) of Human and 
15/10/2021 
21/09/2022 
SmPC, Annex 
Veterinary Medicinal Products - Other variation 
II, Labelling 
and PL 
IB/0023 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
19/07/2021 
09/11/2021 
SmPC, 
To extend the shelf life from 36 months to 48 months when 
life of the finished product - As packaged for sale 
Labelling and 
stored at 2°-8°C and protected from light. 
(supported by real time data) 
PL 
IB/0022 
B.II.z - Quality change - Finished product - Other 
30/06/2021 
n/a 
Page 5/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
variation 
PSUSA/10697
Periodic Safety Update EU Single assessment - 
25/02/2021 
21/04/2021 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/202007 
inotersen 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10697/202007. 
IB/0019 
C.I.11.z - Introduction of, or change(s) to, the 
19/03/2021 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IA/0020 
A.7 - Administrative change - Deletion of 
05/03/2021 
n/a 
manufacturing sites 
IB/0018 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
07/12/2020 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
IA/0017 
B.II.f.1.e - Stability of FP - Change to an approved 
27/11/2020 
n/a 
stability protocol 
IAIN/0016/G 
This was an application for a group of variations. 
16/10/2020 
n/a 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
Page 6/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
PSUSA/10697
Periodic Safety Update EU Single assessment - 
03/09/2020 
n/a 
PRAC Recommendation - maintenance 
/202001 
inotersen 
II/0011 
Update of SmPC section 5.3 to reflect the results of 
03/09/2020 
03/11/2020 
SmPC and PL 
The final report of a 2-year subcutaneous (s.c.) 
rat carcinogenicity study. 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
carcinogenicity study of ISIS 420915 has shown dose-
related incidence of subcutaneous pleomorphic 
fibrosarcoma and subcutaneous fibrosarcoma 
(monomorphic type) at 2 and 6 mg/kg/week in the 
injection site or injection site regions. The human relevance 
of these findings is considered to be low. 
IB/0014 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
14/05/2020 
03/11/2020 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
IB/0013/G 
This was an application for a group of variations. 
22/04/2020 
n/a 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
Page 7/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
specification limits 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
PSUSA/10697
Periodic Safety Update EU Single assessment - 
16/01/2020 
n/a 
PRAC Recommendation - maintenance 
/201907 
inotersen 
IAIN/0010/G 
This was an application for a group of variations. 
22/11/2019 
03/11/2020 
SmPC, Annex 
II and PL 
A.6 - Administrative change - Change in ATC 
Code/ATC Vet Code 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IB/0009/G 
This was an application for a group of variations. 
24/10/2019 
n/a 
B.I.a.2.a - Changes in the manufacturing process of 
Page 8/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
PSUSA/10697
Periodic Safety Update EU Single assessment - 
25/07/2019 
19/09/2019 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/201901 
inotersen 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10697/201901. 
IB/0007 
B.I.b.1.d - Change in the specification parameters 
31/07/2019 
n/a 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
IA/0006/G 
This was an application for a group of variations. 
14/06/2019 
n/a 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
IB/0005 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
10/05/2019 
19/09/2019 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
Page 9/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T/0003 
Transfer of Marketing Authorisation 
01/02/2019 
01/03/2019 
SmPC, 
Labelling and 
PL 
IB/0002 
B.II.d.1.z - Change in the specification parameters 
26/11/2018 
n/a 
and/or limits of the finished product - Other variation 
T/0001 
Transfer of Marketing Authorisation 
28/08/2018 
12/09/2018 
SmPC, 
Labelling and 
PL 
Page 10/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
